Skip to main content
TipRanks
Go Ultimate75% OFF

Mabwell (Shanghai) Bioscience Co., Ltd. Class H (2493) AI Stock Analysis

1 Followers
HK:2493

Mabwell (Shanghai) Bioscience Co., Ltd. Class H

(HKEX:2493)

Select Model
Rating:42Neutral
Price Target:HKD 17.50â–¼(-0.96% Downside)
Action:reiterated
Date:11/04/26

Overall score is constrained primarily by weak financial performance (declining revenue, large operating losses, high leverage, and sustained negative operating/free cash flow). Technicals add additional pressure with price below key moving averages and negative MACD, while valuation remains unattractive due to negative earnings and no dividend support.

Positive Factors
Strong Gross MarginA gross margin near 74.5% indicates that commercial revenue, where generated, can retain substantial value after direct product costs. This provides a favorable base for future operating leverage if the company can grow sales and control research, development, and corporate expenses.
Negative Factors
Declining RevenueA 17.9% TTM revenue decline signals weakening top-line momentum and makes it harder to absorb the company’s substantial fixed research, development, and operating costs. Without a return to sustained growth, the path toward scale economics and breakeven remains uncertain.

Mabwell (Shanghai) Bioscience Co., Ltd. Class H (2493) vs. iShares MSCI Hong Kong ETF (EWH)

-40%-30%-20%-10%0%10%20%HK:2493-36.44%EWH+9.93%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 9.61B
Dividend Yield
―
Average Volume (3M)
191.64K
Price to Earnings (P/E)
-5.8
Beta (1Y)
0.03
Revenue Growth
20.87%
EPS Growth
―
Country
Hong Kong
Employees
1,325
Sector
General
Sector Strength
55
Industry
Biotechnology

Mabwell (Shanghai) Bioscience Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectio...

How the Company Makes Money

Mabwell (Shanghai) Bioscience Co., Ltd. generates revenue primarily through (1) sales of commercialized drug products, if and when its biologics receive regulatory approval and are launched; and (2) collaborations and out-licensing activities related...

Mabwell (Shanghai) Bioscience Co., Ltd. Class H Financial Statement Overview

Summary

Financial profile is high-risk: TTM revenue declined 17.9%, profitability remains deeply negative (TTM net margin about -108%), leverage is elevated (TTM debt-to-equity ~3.84x), and cash burn persists (TTM operating cash flow ~-935M; free cash flow ~-1.04B). Offsetting positives are a strong gross margin (~74.5%) and some improvement versus the worst historical loss intensity and leverage peak.

Income Statement

22Negative

Balance Sheet

28Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Mar 2024Mar 2023Dec 2021
Income Statement
Total Revenue717.92M662.52M199.78M127.84M27.73M15.96M
Gross Profit533.74M598.05M170.83M126.47M27.66M-72.92M
EBITDA-819.99M-647.88M-844.97M-937.63M-858.54M-699.62M
Net Income-1.05B-969.33M-1.04B-1.05B-955.23M-756.86M
Balance Sheet
Total Assets5.30B4.56B4.28B4.46B4.62B1.59B
Cash, Cash Equivalents and Short-Term Investments2.32B1.53B1.20B1.67B2.55B96.37M
Total Debt3.69B2.60B2.07B1.26B752.83M333.98M
Total Liabilities4.40B4.02B2.72B1.88B1.11B574.15M
Stockholders Equity715.70M349.51M1.57B2.58B3.52B1.01B
Cash Flow
Free Cash Flow-1.04B-447.93M-1.29B-1.28B-1.26B-624.47M
Operating Cash Flow-934.77M-290.22M-956.44M-782.73M-719.17M-410.56M
Investing Cash Flow-175.13M-199.31M-291.55M-509.62M-602.80M7.77M
Financing Cash Flow2.00B791.92M831.70M444.94M3.72B195.65M

Mabwell (Shanghai) Bioscience Co., Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

HK:2493 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:2696HK:269665NeutralHKD 23.70B23.2320.41%―32.63%8.74%
HK:1801HK:180163NeutralHKD 145.95B100.266.06%―42.64%9.67%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
HK:9966HK:996645NeutralHKD 5.19B-26.28-10.27%―-31.77%-177.01%
HK:9926HK:992645NeutralHKD 55.53B-48.14-10.86%―42.47%-15.80%
HK:2493HK:249342NeutralHKD 9.54B-5.80-205.41%―20.87%―
HK:1877HK:187741NeutralHKD 27.62B-63.59-7.23%―35.82%54.40%

* General Sector Average

Performance Comparison

-40%-20%0%20%HK:2493HK:1801HK:9926HK:9966HK:1877HK:2696Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:2493 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:2493Mabwell (Shanghai) Bioscience Co., Ltd. Class H17.67-10.13-36.44%
HK:1801Innovent Biologics83.50-8.70-9.44%
HK:9926Akeso, Inc.59.00-54.10-47.83%
HK:9966Alphamab Oncology5.33-4.98-48.30%
HK:1877Shanghai Junshi Biosciences Co., Ltd. Class H13.92-10.64-43.32%
HK:2696Shanghai Henlius Biotech, Inc. Class H43.46-24.14-35.71%

Mabwell (Shanghai) Bioscience Co., Ltd. Class H Corporate Events

Mabwell Issues Unaudited PRC-Standard Q3 2026 Results and Cautions Investors

Oct 28, 2026

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical group listed in Hong Kong and on Shanghai’s STAR Market, has released its unaudited 2026 third-quarter financial report prepared under PRC accounting standards. The board and senior managem...

Mabwell Showcases Promising ADC Breast Cancer Data as 9MW2821 Advances Across Pivotal Trials

Oct 19, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. announced that Phase II clinical data for its innovative Nectin-4-targeted ADC 9MW2821 in patients with locally advanced or metastatic triple-negative breast cancer previously treated with topoisomerase I inhib...

Mabwell Schedules Board Meeting to Approve Third-Quarter Results

Oct 15, 2026

Mabwell (Shanghai) Bioscience Co., Ltd., a Hong Kong-listed bioscience and biopharmaceutical company, operates through a group structure in the PRC with a board that includes both executive and independent non-executive directors. The firm targets th...

Mabwell Shareholders Back SynuSight Deals and Business Scope Change

Sep 17, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. announced that its 2026 fourth extraordinary general meeting was duly convened in Shanghai and all directors attended, with legal advisers confirming compliance with PRC laws and the company’s articles. Shareho...

Mabwell Reports Positive COPD Data for 9MW1911 Ahead of ERS 2026

Sep 4, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. will present updated Phase Ib/IIa clinical data for its innovative monoclonal antibody 9MW1911 in former smokers with moderate-to-severe COPD at the European Respiratory Society Congress 2026 in Barcelona. The...

Mabwell Narrows Interim Loss as Revenue Surges in First Half of 2026

Aug 30, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. reported a sharp rise in interim revenue to RMB312.45 million for the six months ended June 30, 2026, up from RMB101.10 million a year earlier. Despite this strong top-line growth, the company remained loss-mak...

Mabwell Plans Expanded Business Scope and Governance Update

Aug 30, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. has approved resolutions to significantly expand and refine its business scope to cover a broad range of technical services, medical and agricultural research, genetic diagnosis and cell technology, as well as...

Mabwell Calls Extraordinary Meeting to Approve SynuSight Deals and Business Scope Change

Aug 30, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. has convened its fourth extraordinary general meeting for 2026 to seek shareholder approval on key business resolutions, including entering into a license agreement with SynuSight and jointly applying for a sci...

Mabwell Sets Board Meeting to Approve 2026 Interim Results

Aug 19, 2026

Mabwell (Shanghai) Bioscience Co., Ltd., a PRC-based biopharmaceutical group listed in Hong Kong under stock code 2493, develops and commercializes bioscience innovations, supported by a board comprising executive and independent non-executive direct...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026